283 related articles for article (PubMed ID: 34499822)
1. Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis.
Anderson A; McCoy L; Pettit RS; Wright BA; Lubsch L
Pediatr Pulmonol; 2021 Dec; 56(12):4053-4054. PubMed ID: 34499822
[No Abstract] [Full Text] [Related]
2. Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis.
Lee TWR; Duff AJA
Am J Respir Crit Care Med; 2024 Feb; 209(3):239-241. PubMed ID: 38113403
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Advanced Cystic Fibrosis Lung Disease.
Djavid AR; Thompson AE; Irace AL; Gusman E; Altman K; DiMango EA; Keating CL
Ann Am Thorac Soc; 2021 Nov; 18(11):1924-1927. PubMed ID: 34000224
[No Abstract] [Full Text] [Related]
5. Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.
O'Shea KM; O'Carroll OM; Carroll C; Grogan B; Connolly A; O'Shaughnessy L; Nicholson TT; Gallagher CG; McKone EF
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33154033
[No Abstract] [Full Text] [Related]
6. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.
Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
8. Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children.
Nathan N; Thouvenin G; Dubern B; Corvol H
Pediatr Pulmonol; 2024 Mar; 59(3):788-790. PubMed ID: 38088210
[No Abstract] [Full Text] [Related]
9. Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?
Merrill TB; Tyes J; Woodard TD
Laryngoscope; 2024 Feb; 134(2):501-503. PubMed ID: 37548273
[No Abstract] [Full Text] [Related]
10. Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study.
Salvatore D; Cimino G; Troiani P; Bignamini E; Esposito I; Leonetti G; Zanda M; Manunza D; Pepe A
Pediatr Pulmonol; 2022 Sep; 57(9):2253-2256. PubMed ID: 35577767
[No Abstract] [Full Text] [Related]
11. Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort.
Bacon DR; Stapleton A; Goralski JL; Ebert CS; Thorp BD; Nouraie M; Shaffer AD; Senior BA; Lee SE; Zemke AC; Kimple AJ
Int Forum Allergy Rhinol; 2022 Feb; 12(2):223-226. PubMed ID: 34709729
[No Abstract] [Full Text] [Related]
12. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
Smith S; Borchardt M
J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
[No Abstract] [Full Text] [Related]
13. Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
Dooney M; Saba T
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423592
[No Abstract] [Full Text] [Related]
14. Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
Burgel PR
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423591
[No Abstract] [Full Text] [Related]
15. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
16. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
Terlizzi V
J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
[No Abstract] [Full Text] [Related]
17. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare
Burgel PR; Sermet-Gaudelus I; Girodon E; Kanaan R; Le Bihan J; Remus N; Ravoninjatovo B; Grenet D; Porzio M; Houdouin V; Le Clainche-Viala L; Durieu I; Nove-Josserand R; Languepin J; Coltey B; Guillaumot A; Audousset C; Chiron R; Weiss L; Fajac I; Da Silva J; Martin C;
Eur Respir J; 2024 Jan; 63(1):. PubMed ID: 38242629
[No Abstract] [Full Text] [Related]
18. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
19. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
Hoy SM
Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
[TBL] [Abstract][Full Text] [Related]
20. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]